MADRIGAL PHARMACEUTICALS, INC.MDGLEarnings & Financial Report
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
MDGL Q4 2025 Key Financial Metrics
売上高
$321.1M
粗利益
N/A
営業利益
$-59.6M
純利益
$-58.6M
粗利益率
N/A
営業利益率
-18.6%
純利益率
-18.2%
前年比成長
210.8%
EPS
$-2.55
資金フロー
MADRIGAL PHARMACEUTICALS, INC. Q4 2025 Financial Summary
MADRIGAL PHARMACEUTICALS, INC. reported revenue of $321.1M (up 210.8% YoY) for Q4 2025, with a net profit of $-58.6M (up 1.4% YoY) (-18.2% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $321.1M |
|---|---|
| Net Profit | $-58.6M |
| Gross Margin | N/A |
| Operating Margin | -18.6% |
| Report Period | Q4 2025 |
Revenue Breakdown
MADRIGAL PHARMACEUTICALS, INC. Q4 2025 revenue of $321.1M breaks down across 3 segments, led by Rebates Customer Fees Credits Co Pay Assistance And Other at $208.5M (64.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Rebates Customer Fees Credits Co Pay Assistance And Other | $208.5M | 64.9% |
| Other | $76.0M | 23.7% |
| Chargebacks Discounts For Prompt Pay And Other Allowances | $36.6M | 11.4% |
MADRIGAL PHARMACEUTICALS, INC. Annual Revenue by Year
MADRIGAL PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $958.4M). Click any linked year to see what changed vs the prior 10-K.
MADRIGAL PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
MADRIGAL PHARMACEUTICALS, INC. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $321.1M | +210.8% | $-58.6M | -18.2% |
| Q3 2025 | $287.3M | +362.0% | $-114.2M | -39.8% |
| Q2 2025 | $212.8M | +1353.8% | $-42.3M | -19.9% |
| Q1 2025 | $137.3M | — | $-73.2M | -53.4% |
| Q4 2024 | $103.3M | — | $-59.4M | -57.5% |
| Q3 2024 | $62.2M | — | $-107.0M | -172.0% |
| Q2 2024 | $14.6M | — | $-152.0M | -1038.2% |
| Q1 2024 | $0 | — | $-147.5M | N/A |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $0 | $14.6M | $62.2M | $103.3M | $137.3M | $212.8M | $287.3M | $321.1M |
| 前年比成長 | N/A | N/A | N/A | N/A | N/A | 1353.8% | 362.0% | 210.8% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $1.08B | $1.10B | $1.07B | $1.04B | $996.6M | $1.02B | $1.36B | $1.26B |
| 総負債 | $231.5M | $242.7M | $296.1M | $287.9M | $286.0M | $319.4M | $736.7M | $656.9M |
| 株主資本 | $850.8M | $857.1M | $777.2M | $754.4M | $710.6M | $696.0M | $625.7M | $602.7M |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $-149.2M | $-134.9M | $-67.0M | $-104.5M | $-88.9M | $-47.1M | $79.8M | $-133.5M |